Multicenter double-blind randomized phase II: FOLFOX plus ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA)

被引：20
|
作者：
Enzinger, Peter C.
McCleary, Nadine Jackson
Zheng, Hui
Abrams, Thomas Adam
Yurgelun, Matthew B.
Azzoli, Christopher G.
Cleary, James M.
Rubinson, Douglas Adam
Brooks, Gabriel
Chan, Jennifer A.
Goyal, Lipika
Meyerhardt, Jeffrey A.
Ng, Kimmie
Schrag, Deborah
Savarese, Diane M. F.
Graham, Christopher
Carey, Margaret M.
Fuchs, Charles S.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[4] MGH Canc Ctr, Brookline, MA USA
[5] Div Hematol Oncol, Waltham, MA USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial
    Cleary, James M.
    Horick, Nora K.
    McCleary, Nadine Jackson
    Abrams, Thomas A.
    Yurgelun, Matthew B.
    Azzoli, Christopher G.
    Rubinson, Douglas A.
    Brooks, Gabriel A.
    Chan, Jennifer A.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Ng, Kimmie
    Schrag, Deborah
    Savarese, Diane M. F.
    Graham, Christopher
    Fitzpatrick, Bridget
    Gibb, Kathryn A.
    Boucher, Yves
    Duda, Dan G.
    Jain, Rakesh K.
    Fuchs, Charles S.
    Enzinger, Peter C.
    CANCER, 2019, 125 (13) : 2213 - 2221
  • [2] A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naive advanced or metastatic biliary tract cancer: first safety and efficacy data
    Moehler, M.
    Kanzler, S.
    Schimanski, C. C.
    Woerns, M. A.
    Denzer, U.
    Kolligs, F.
    Ebert, M.
    Distelrath, A.
    Zeuzem, S.
    Lammert, F.
    Geissler, M.
    Lohse, A.
    Dollinger, M.
    Lindig, U.
    Duerr, M.
    Lubomierski, N.
    Kabisch, M.
    Schadmand-Fischer, S.
    Galle, P. R.
    ONKOLOGIE, 2011, 34 : 217 - 217
  • [3] A phase II study of ziv-aflibercept (Z) plus FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).
    Satoh, Taroh
    Denda, Tadamichi
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Sasaki, Toru
    Sunaga, Yoshinori
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naive Pancreatic Adenocarcinoma
    Cohen, Steven J.
    Zalupski, Mark M.
    Conkling, Paul
    Nugent, Francis
    Ma, Wen Wee
    Modiano, Manuel
    Pascual, Rolan
    Lee, Fa Chyi
    Wong, Lucas
    Hersh, Evan
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 230 - 235
  • [5] CEDIRANIB plus FOLFOX/XELOX VERSUS PLACEBO plus FOLFOX/XELOX IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY (HORIZON II)
    Hoff, P. M.
    Hochhaus, A.
    Pestalozzi, B. C.
    Tebbutt, N. C.
    Li, J.
    Kim, T. W.
    Pike, L.
    Fielding, A.
    Robertson, J.
    Saunders, M. P.
    ANNALS OF ONCOLOGY, 2010, 21 : 9 - 9
  • [6] Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
    Hoff, Paulo M.
    Hochhaus, Andreas
    Pestalozzi, Bernhard C.
    Tebbutt, Niall C.
    Li, Jin
    Kim, Tae Won
    Koynov, Krassimir D.
    Kurteva, Galina
    Pinter, Tamas
    Cheng, Ying
    van Eyll, Brigitte
    Pike, Laura
    Fielding, Anitra
    Robertson, Jane D.
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3596 - 3603
  • [7] A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
    Cui, Chuanliang
    Mao, Lili
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Li, Siming
    Lian, Bin
    Gu, Kangsheng
    Tao, Min
    Song, Xin
    Lin, Tongyu
    Ren, Xiubao
    Qin, Shukui
    Guo, Jun
    MOLECULAR THERAPY, 2013, 21 (07) : 1456 - 1463
  • [8] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM).
    Kindler, HL
    Karrison, T
    Lu, C
    Gandara, DR
    Stevenson, J
    Krug, L
    Janne, P
    Guterz, TL
    Stadler, WM
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 625S - 625S
  • [10] Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) plus FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC).
    Yoshino, Takayuki
    Sugimoto, Naotoshi
    Yamazaki, Kentaro
    Kajiwara, Takeshi
    Komatsu, Yoshito
    Sasaki, Toru
    Chiron, Marielle
    Ziti-Ljajic, Samira
    Brillac, Claire
    Hamaguchi, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345